This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genzyme CEO Defends Tenure as Icahn Lurks

SAN FRANCISCO (TheStreet) -- Embattled Genzyme (GENZ) CEO Henri Termeer told a packed room of investors Tuesday that he accepted responsibility for the manufacturing problems that have crippled the biotech firm this year. But he also insisted that he's the best man to lead the company's recovery.

"I accept with great humility that these manufacturing interruptions have happened under my watch," said Termeer, in response to my question about why he should remain the company's chief executive.

Henri Termeer
Genzyme's CEO Henri Termeer
Termeer spent a good bit of his 30-minute breakout session at the J.P. Morgan Healthcare Conference outlining the steps Genzyme is taking to recover from a year's worth of manufacturing problems that caused drug shortages, a drop in earnings and a plunging stock price.

But investors I spoke with remain unconvinced that Termeer can get the job done, which may be why Genzyme's stock price seems to move higher only when the talk turns to speculation about proxy fights and management housecleaning.

Towards that end, one investor in the breakout session asked Termeer if Genzyme has had any contact with billionaire hedge fund manager and activist shareholder Carl Icahn.

"We've had no discussions with Mr. Icahn," replied Termeer. "No contact."

Icahn owns 1.5 million Genzyme shares as of the third quarter and speculation is building that he's buying more stock to prepare for a proxy fight.

Alex Denner, Icahn's biotech lieutenant, was spotted in the room during Termeer's talk but had nothing to say publicly. (More than a few people turned to glance at Denner after Termeer responded to the Icahn question, as if expecting him to stand up and counterpunch.)

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,864.14 -47.97 -0.28%
S&P 500 1,969.43 -0.52 -0.03%
NASDAQ 4,459.85 +17.1520 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs